natgillin/translations-raw huggingface dataset:
Sildenafil Teva is contraindicated in patients who have loss of vision in one eye because of nonarteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4). 
Sildenafil Teva je kontraindiciran u bolesnika koji su izgubili vid na jednom oku zbog nearteritične anteriorne ishemijske optičke neuropatije (NAION), bez obzira je li ta epizoda bila u vezi ili ne s prethodnom izloženošću PDE5 inhibitoru (vidjeti dio 4.4).
Given sildenafil peak plasma concentrations of approximately 1 μM after recommended doses, it is unlikely that Sildenafil Teva will alter the clearance of substrates of these isoenzymes. 
S obzirom da su nakon preporučenih doza vršne koncentracije sildenafila u plazmi približno 1 µM, nije vjerojatno da će Sildenafil Teva promijeniti klirens supstrata tih izoenzima.
In a penile plethysmography (RigiScan) study of fasted patients, the median time to onset for those who obtained erections of 60 % rigidity (sufficient for sexual intercourse) was 25 minutes (range 12-37 minutes) on sildenafil. 
Ispitivanjem pomoću penilne pletizmografije (RigiScan) u bolesnika natašte, medijan vremena do pojave za one koji su postigli erekcije od 60% rigiditeta (dovoljno za spolni odnos) iznosila je 25 minuta (raspon 12-37 minuta) za sildenafil.
Since sildenafil (and its major circulating N-desmethyl metabolite) is 96 % bound to plasma proteins, this results in the mean maximum free plasma concentration for sildenafil of 18 ng/mL (38 nM). 
Budući da je sildenafil (i njegov glavni cirkulirajući N­dezmetil metabolit) 96% vezan na proteine u plazmi, to rezultira srednjom maksimalnom koncentracijom slobodnog sildenafila u plazmi od 18 ng/ml (38 nM).
Sildenafil Teva potentiates the hypotensive effect of nitrates (see section 4.3). 
Sildenafil Teva pojačava hipotenzivne učinke nitrata (vidjeti dio 4.3).
You should not take Sildenafil Teva if you do not have erectile dysfunction. 
Ne smijete uzimati Sildenafil Teva ako nemate poremećaj erekcije.
How to store Sildenafil Teva Contents of the pack and other information 
Kako čuvati Sildenafil Teva Sadržaj pakiranja i druge informacije
Some patients who take alpha-blocker therapy for the treatment of high blood pressure or prostate enlargement may experience dizziness or light-headedness, which may be caused by low blood pressure upon sitting or standing up quickly. 
Pojedini bolesnici koji uzimaju alfa-blokatore za liječenje visokog krvnog tlaka ili povećanja prostate mogu imati omaglicu ili nesvjesticu, što može biti uzrokovano sniženjem krvnog tlaka nakon naglog uspravljanja u sjedeći ili stojeći položaj.
In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 200 % and 79 % respectively. 
Nadalje, vrijednosti AUC i Cmax N­dezmetil metabolita bile su značajno povećane, 200% odnosno 79%.
• A sudden decrease or loss of vision - this occurs rarely 
• Iznenadno smanjenje ili gubitak vida - javlja se rijetko
In fixed dose studies, the proportions of patients reporting that treatment improved their erections were 62 % (25 mg), 74 % (50 mg) and 82 % (100 mg) compared to 25 % on placebo. 
U ispitivanjima s fiksnom dozom, udjeli bolesnika koji su prijavili da im je liječenje poboljšalo erekciju iznosili su 62% (25 mg), 74% (50 mg) i 82% (100 mg) u usporedbi s 25% kod placeba.
Sildenafil Teva should not be given to individuals under the age of 18. 
Sildenafil Teva se ne smije davati osobama mlađim od 18 godina.
− If you are allergic to sildenafil or any of the other ingredients of this medicine (listed in section 
• Ako ste alergični na Sildenafil ili neki drugi sastojak ovog lijeka (naveden u dijelu 6)
Of note, most, but not all, of the men who experienced these side effects had heart problems before taking this medicine. 
Potrebno je napomenuti kako je većina muškaraca, ali ne svi, koja je imala navedene nuspojave, imala je poteškoće sa srcem već prije uzimanja ovog lijeka.
Other medicines and Sildenafil Teva 
Drugi lijekovi i Sildenafil Teva
Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 90 % higher plasma concentrations of sildenafil and the active N-desmethyl metabolite compared to those seen in healthy younger volunteers (18-45 years). 
Zdravi stariji dobrovoljci (65 godina ili stariji) imali su smanjeni klirens sildenafila, što je rezultiralo približno 90% višim koncentracijama sildenafila i aktivnog N-dezmetil metabolita u plazmi u usporedbi s koncentracijama opaženim u zdravih mlađih dobrovoljaca (18-45 godina).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
Unutar svake skupine učestalosti, nuspojave su prikazane prema ozbiljnosti,
In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite. 
U normalnih, zdravih muških dobrovoljaca, nije bilodokaza o utjecaju azitromicina (500 mg dnevno tijekom 3 dana) na AUC, Cmax, tmax, konstantu brzine eliminacije ili poluvrijeme sildenafila ili njegovog glavnog cirkulirajućeg metabolita.
Sildenafil is an oral therapy for erectile dysfunction. 
Mehanizam djelovanja Sildenafil je oralna terapija za erektilnu disfunkciju.
Based on efficacy and tolerability, the dose may be increased step-wise to 50 mg up to 100 mg as necessary. 
Na temelju djelotvornosti i podnošljivosti, doza se može postupno povisiti na 50 mg i 100 mg prema potrebi.
The dosing recommendations described in ‘Use in adults' apply to patients with mild to moderate renal impairment (creatinine clearance = 30 - 80 mL/min). 
Preporuke za doziranje opisane pod „Primjena u odraslih osoba“ odnose se na bolesnike s blagim do umjerenim oštećenjem funkcije bubrega (klirens kreatinina = 30-80 ml/min).
Certain patients have experienced these symptoms when taking Sildenafil Teva with alpha-blockers. 
Određeni bolesnici su imali te simptome prilikom uzimanja lijeka Sildenafil Teva s alfa-blokatorima.
The following patient groups were represented: elderly (19.9 %), patients with hypertension (30.9 %), diabetes mellitus (20.3 %), ischaemic heart disease (5.8 %), hyperlipidaemia (19.8 %), spinal cord injury (0.6 %), depression (5.2 %), transurethral resection of the prostate (3.7 %), radical prostatectomy 
Zastupljene su sljedeće skupine bolesnika: stariji (19,9%), bolesnici s hipertenzijom (30,9%), dijabetes melitusom (20,3%), ishemijskom bolesti srca (5,8%), hiperlipidemijom (19,8%), ozljedom leđne moždine (0,6%), depresijom (5,2%), transuretralnom resekcijom prostate (3,7%), radikalnom prostatektomijom (3,3%).
− If you currently have a stomach ulcer, or a bleeding problem (such as haemophilia). 
• Ako trenutno imate čir na želucu ili probleme s krvarenjem (kao što je hemofilija).
Sildenafil Teva is not indicated for use by women. 
Sildenafil Teva nije namijenjen za primjenu u žena.
• Prolonged and sometimes painful erections - this occurs rarely (may affect up to 1 in 1,000 people) 
• Produljene i ponekad bolne erekcije - javljaju se rijetko (mogu se javiti kod do 1 na 1000 osoba)
Doses of 200 mg did not result in increased efficacy but the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, altered vision) was increased. 
Doze od 200 mg nisu rezultirale povećanom djelotvornošću, već je porasla incidencija nuspojava (glavobolja, crvenilo uz osjećaj vrućine, omaglica, dispepsija, nazalna kongestija, promijenjen vid).
The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated: severe hepatic impairment, hypotension (blood pressure <90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases). 
Sigurnost sildenafila nije ispitana u sljedećim podskupinama bolesnika te je njegova primjena stoga kontraindicirana: teško oštećenje jetre, hipotenzija (krvni tlak <90/50 mm Hg), anamneza nedavnog moždanog udara ili infarkta miokarda i poznati nasljedni degenerativni poremećaji retine kao što su retinitis pigmentosa (manji dio tih bolesnika ima genetske poremećaje retinalnih fosfodiesteraza).
Film coat: poly(vinyl alcohol), titanium dioxide (E171), macrogol 3350, talc. 
Film ovojnica: poli(vinilni alkohol), titanijev dioksid (E171), makrogol 3350, talk.
The mean AUC and Cmax of the N-desmethyl metabolite increased up to 126 % and up to 73 % respectively, compared to age-matched volunteers with no renal impairment. 
Srednja AUC i Cmax N-dezmetil metabolita porasla je do 126% odnosno do 73%, u usporedbi s dobrovoljcima odgovarajućim po dobi, bez oštećenja bubrega.
The safety and efficacy of combinations of sildenafil with other PDE5 Inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil , or other treatments for erectile dysfunction have not been studied. 
Sigurnost i djelotvornost kombinacija sildenafila s drugim inhibitorima PDE5, s drugim terapijama za plućnu arterijsku hipertenziju (PAH) koje sadrže sildenafil ili s drugim oblicima liječenja erektilne disfunkcije nije ispitana.
In these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were observed. 
U ispitivanoj populaciji uočena su srednja dodatna sniženja krvnog tlaka u ležećem položaju od 7/7 mmHg, 9/5 mmHg odnosno 8/4 mmHg te srednja dodatna sniženja krvnog tlaka u stojećem položaju od 6/6 mmHg, 11/4 mmHg odnosno 4/5 mmHg.
In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (>70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline. 
U ispitivanju hemodinamičkih učinaka jednokratne oralne doze sildenafila od 100 mg u 14 bolesnika s teškom bolesti koronarnih arterija (> 70% stenoza barem jedne koronarne arterije), srednji sistolički i dijastolički krvni tlak u mirovanju je snižen za 7%, odnosno 6% u usporedbi s početnom vrijednosti.
Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru i kutiji iza „EXP“.
Two clinical studies were specifically designed to assess the time window after dosing during which sildenafil could produce an erection in response to sexual stimulation. 
Klinička djelotvornost i sigurnost Dva klinička ispitivanja posebno su dizajnirana kako bi se procijenio vremenski okvir nakon doziranja tijekom kojeg bi sildenafil mogao dovesti do erekcije u odgovoru na seksualnu stimulaciju.
Table 1: Medically important adverse reactions reported at an incidence greater than placebo in controlled clinical studies and medically important adverse reactions reported through postmarketing surveillance 
Tablica 1: Medicinski značajne nuspojave zabilježene s učestalošću većom od placeba u kontroliranim kliničkim ispitivanjima i medicinski značajne nuspojave zabilježene u razdoblju nakon stavljanja lijeka u promet Klasifikacija organskih sustava
− If you have ever had loss of vision due to non-arteritic anterior ischaemic optic neuropathy 
• Ako ste ikada imali gubitak vida zbog nearteritične prednje ishemijske optičke neuropatije
Poly(vinyl alcohol) Titanium dioxide (E171) Macrogol 3350 
Film ovojnica poli(vinilni alkohol) titanijev dioksid (E171) makrogol 3350 talk
Cerebrovascular accident, Transient ischaemic attack, Seizure,* Seizure recurrence,* Syncope 
Cerebrovaskularni inzult, tranzitorna ishemijska ataka, napadaji,* ponavljanje napadaja,* sinkopa
To reduce the chance that these symptoms might happen, you should be on a regular daily dose of your alpha-blocker before you start Sildenafil Teva. 
Kako bi se smanjila mogućnost pojave tih simptoma, trebate biti na redovitoj dnevnoj dozi alfa-blokatora prije nego počnete uzimati Sildenafil Teva.
Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56 % increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers. 
(800 mg), inhibitor citokroma P450 i nespecifični CYP3A4 inhibitor, uzrokovao je 56%-tni porast koncentracija sildenafila u plazmi kada se primjenjivao istodobno sa sildenafilom (50 mg) u zdravih dobrovoljaca.
Stevens-Johnson Syndrome (SJS),* Toxic Epidermal Necrolysis (TEN)* 
Stevens-Johnsonov sindrom (SJS), *
Across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84 %), mixed erectile dysfunction (77 %), organic erectile dysfunction (68 %), elderly (67 %), diabetes mellitus (59 %), ischaemic heart disease (69 %), hypertension (68 %), TURP (61 %), radical prostatectomy (43 %), spinal cord injury (83 %), depression (75 %). 
Uzimajući u obzir sva ispitivanja, udio bolesnika koji su prijavili poboljšanje uz sildenafil bio je sljedeći: psihogena erektilna disfunkcija (84%), mješovita erektilna disfunkcija (77%), organska erektilna disfunkcija (68%), starije osobe (67%), dijabetes melitus (59%), ishemična bolest srca (69%), hipertenzija (68%), TURP (61%), radikalna prostatektomija (43%), ozljeda leđne moždine
Serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported post-marketing in temporal association with the use of sildenafil. 
Teški kardiovaskularni događaji, uključujući infarkt miokarda, nestabilnu anginu, iznenadnu srčanu smrt, ventrikularnu aritmiju, cerebrovaskularno krvarenje, tranzitornu ishemijsku ataku, hipertenziju i hipotenziju bili su prijavljeni u razdoblju nakon stavljanja lijeka u promet, kao vremenski povezani s primjenom sildenafila.
Do not take Sildenafil Teva film-coated tablets in combination with sildenafil-containing orodispersible tablets. 
Nemojte uzeti Sildenafil Teva filmom obložene tablete u kombinaciji s raspadljivim tabletama za usta koje sadrže sildenafil.
− If you experience sudden decrease or loss of vision, stop taking Sildenafil Teva and contact your doctor immediately. 
• Ako osjetite iznenadno slabljenje ili gubitak vida, prestanite uzimati Sildenafil Teva i odmah zatražite savjet liječnika.
If you experience any of the following serious side effects stop taking Sildenafil Teva and seek medical help immediately: 
Ako primijetite bilo koju od sljedećih nuspojava, prestanite uzimati lijek Sildenafil Teva i odmah zatražite medicinsku pomoć:
You should not use Sildenafil Teva with treatments for pulmonary arterial hypertension (PAH) containing sildenafil or any other PDE5 inhibitors. 
Ne smijete uzimati Sildenafil Teva zajedno s terapijom za plućnu arterijsku hiperteniziju (PAH) koja sadrži sildenafil ili neke druge inhibitore PDE5.
Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates). 
Iako specifična ispitivanja interakcija nisu provedena za sve lijekove, populacijska farmakokinetička analiza nije ukazala na djelovanje istodobno primijenjenih terapija na farmakokinetiku sildenafila, grupiranih kao CYP2C9 inhibitori (kao što su tolbutamid, varfarin, fenitoin), CYP2D6 inhibitori (kao što su selektivni inhibitori ponovne pohrane serotonina, triciklični antidepresivi), tiazid i srodni diuretici, diuretici Henleove petlje i oni koji štede kalij, inhibitori angiotenzin konvertirajućeg enzima,
*Reported during post-marketing surveillance only **Visual colour distortions: Chloropsia, Chromatopsia, Cyanopsia, Erythropsia and Xanthopsia ***Lacrimation disorders: Dry eye, Lacrimal disorder and Lacrimation increased 
*Prijavljeno isključivo nakon stavljanja lijeka u promet ** Vizualni poremećaj percepcije boja: kloropsija, kromatopsija,cijanopsija, eritropsija i ksantopsija *** Poremećaji suzenja: suho oko, suzni poremećaji i pojačano suženje
The following groups were not well represented or excluded from clinical trials: patients with pelvic surgery, patients post-radiotherapy, patients with severe renal or hepatic impairment and patients with certain cardiovascular conditions (see section 4.3). 
Sljedeće skupine nisu dobro zastupljene ili su isključene iz kliničkih ispitivanja: bolesnici s operacijom u području zdjelice, bolesnici nakon radioterapije, bolesnici s teškim poremećajem funkcije bubrega ili jetre i bolesnici s određenim kardiovaskularnim stanjima
How to take Sildenafil Teva 
Kako uzimati Sildenafil Teva
− If you have sickle cell anaemia (an abnormality of red blood cells), leukaemia (cancer of blood cells), multiple myeloma (cancer of bone marrow) 
• Ako imate anemiju srpastih stanica (poremećaj crvenih krvnih stanica), leukemiju (zloćudnu bolest krvnih stanica), multipli mijelom (zloćudnu bolest koštane srži)
Paediatric population Sildenafil Teva is not indicated for individuals below 18 years of age. 
Pedijatrijska populacija Sildenafil Teva nije indiciran za primjenu u osoba mlađih od 18 godina.
Store in the original package in order to protect from moisture 
Čuvati u originalnom pakiranju radi zaštite od vlage
Common (≥ 1/100 and 
(≥ 1/100 do
Always tell your doctor, pharmacist or nurse if you are taking any of these medicines that are often used for the relief of angina pectoris (or “chest pain”). 
Uvijek obavijestite svog liječnika, ljekarnika ili medicinsku sestru ako uzimate bilo koji od ovih lijekova koji se često primjenjuju za ublažavanje angine pektoris (ili boli u prsima).
In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh A and B) sildenafil clearance was reduced, resulting in increases in AUC (84 %) and Cmax (47 %) compared to age-matched volunteers with no hepatic impairment. 
U dobrovoljaca s blagom do umjerenom cirozom jetre (Child-Pugh A i B) klirens sildenafila bio je snižen, što je rezultiralo porastom AUC (84%) i Cmax (47%) u usporedbi s dobrovoljcima odgovarajućim po dobi bez oštećenja jetre.
Myocardial infarction, Ventricular arrhythmia,* Atrial fibrillation, Unstable angina 
Iznenadna srčana smrt,* infarkt miokarda, ventrikularna aritmija,* fibrilacija atrija, nestabilna angina
Sildenafil Teva contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5(PDE5) inhibitors. 
Sildenafil Teva sadrži djelatnu tvar sildenafil koja pripada skupini lijekova pod nazivom inhibitori fosfodiesteraze tipa 5 (PDE5).
31-546, Krakow, Poland 
Teva Operations Poland Sp.z.o.o. ul Mogilska 80. 31-546, Krakow, Poljska
Uncommon (may affect up to 1 in 100 people): vomiting, skin rash, eye irritation, bloodshot eyes /red eyes, eye pain, seeing flashes of light, visual brightness, light sensitivity, watery eyes, pounding heartbeat, rapid heartbeat, high blood pressure, low blood pressure, muscle pain, feeling sleepy, reduced sense of touch, vertigo, ringing in the ears, dry mouth, blocked or stuffy sinuses, inflammation of the lining of the nose (symptoms include runny nose, sneezing and stuffy nose), upper abdominal pain, gastro-oesophageal reflux disease (symptoms include heartburn), presence of blood in urine, pain in the arms or legs, nosebleed, feeling hot and feeling tired. 
Manje često (mogu se javiti kod najviše 1 na 100 osoba): povraćanje, kožni osip, iritacija oka, krvave oči/crvene oči, bol u očima, bljeskovi pred očima, osjećaj svjetline pri gledanju, osjetljivost na svjetlo, suzenje očiju, lupanje srca, ubrzani otkucaji srca, visoki krvni tlak, niski krvni tlak, bol u mišićima, osjećaj pospanosti, smanjeni osjet dodira, vrtoglavica, zvonjenje u ušima, suha usta, puni ili začepljeni sinusi, upala nosne sluznice (simptomi uključuju curenje iz nosa, kihanje i začepljen nos), bol u gornjem dijelu abdomena, gastroezofagealna refluksna bolest (simptomi uključuju žgaravicu), krv u mokraći, bol u rukama ili nogama, krvarenje iz nosa, osjećaj vrućine i osjećaj umora.
Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the coadministration may lead to symptomatic hypotension in a few susceptible individuals (see section 4.5). 
Prilikom primjene sildenafila u bolesnika koji uzimaju alfa-blokator savjetuje se oprez jer istodobna primjena može dovesti do simptomatske hipotenzije u manjeg broja osjetljivih osoba (vidjeti dio 4.5).
The side effects reported in association with the use of Sildenafil Teva are usually mild to moderate and of a short duration. 
Nuspojave zabilježene kod primjene lijeka Sildenafil Teva obično su blage do umjerene i kratko traju.
Non-arteritic anterior ischaemic optic neuropathy (NAION), * Retinal vascular occlusion,* Retinal haemorrhage, Arteriosclerotic retinopathy, Retinal disorder, Glaucoma, Visual field defect, 
Nearteritična anteriorna ishemijska optička neuropatija (NAION), * retinalna vaskularna okluzija,* retinalno krvarenje, arteriosklerotska retinopatija, porem ećaj mrežnice,
− If you are taking medicines called nitrates, as the combination may lead to a dangerous fall in your blood pressure. 
• Ako uzimate lijekove koji se nazivaju nitrati, jer kombinacija može dovesti do opasnog pada krvnog tlaka.
Pooling of the following classes of antihypertensive medication: diuretics, beta-blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive medicinal products (vasodilator and centrallyacting), adrenergic neurone blockers, calcium channel blockers and alpha-adrenoceptor blockers, showed no difference in the side effect profile in patients taking sildenafil compared to placebo treatment. 
inhibitora, antagonista angiotenzina II, antihipertenzivnih lijekova (vazodilatatora i onih sa središnjim djelovanjem), blokatora adrenergičkog neurona, blokatora kalcijevih kanala i blokatora alfaadrenoceptora, nije pokazala razlike u profilu nuspojava u bolesnika koji uzimaju sildenafil u usporedbi s liječenjem placebom.
The safety profile of sildenafil is based on 9,570 patients in 74 double-blind placebo-controlled clinical studies. 
Profil sigurnosti sildenafila temelji se na podacima dobivenim od 9570 bolesnika koji su sudjelovali u
In volunteers with severe renal impairment (creatinine clearance <30 mL/min), sildenafil clearance was reduced, resulting in mean increases in AUC and Cmax of 100 % and 88 % respectively compared to age-matched volunteers with no renal impairment. 
U dobrovoljaca s teškim poremećajem bubrega (klirens kreatinina <30 ml/min), klirens sildenafila bio je snižen, što je rezultiralo srednjim porastom AUC i Cmax od 100%, odnosno 88% u usporedbi s dobrovoljcima odgovarajućim po dobi bez oštećenja bubrega.
2 film-coated tablets 4 film-coated tablets 8 film-coated tablets 10 x 1 film-coated tablet 12 film-coated-tablets 24 film-coated tablets 
2 filmom obložene tablete 4 filmom obložene tablete 8 filmom obloženih tableta 10 x 1 filmom obloženih tableta 12 filmom obloženih tableta 24 filmom obloženih tableta
You may experience an increase in side effects and their severity. 
Mogli biste imati brojnije i jače nuspojave.
In order to minimise the potential for developing postural hypotension, patients should be hemodynamically stable on alpha-blocker therapy prior to initiating sildenafil treatment. 
Kako bi se smanjila mogućnost razvoja posturalne hipotenzije, bolesnici moraju biti hemodinamički stabilni uz liječenje alfa blokatorom prije početka liječenja sildenafilom.